# Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

> **NCT05285384** · NA · COMPLETED · sponsor: **Cinnagen** · enrollment: 43 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant

## Key facts

- **NCT ID:** NCT05285384
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-04
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05285384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05285384, "Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05285384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*